Please login to the form below

Not currently logged in
Email:
Password:

NVX-CoV2373

This page shows the latest NVX-CoV2373 news and features for those working in and with pharma, biotech and healthcare.

Novavax’s BA.1 COVID-19 booster shows strong immune response in phase 3 trial

Novavax’s BA.1 COVID-19 booster shows strong immune response in phase 3 trial

Novavax has announced topline results from a phase 3 trial of its COVID-19 vaccines, showing that its Omicron-adapted BA.1 vaccine candidate, NVX-CoV2515, met the primary strain-change ... The trial included the company's bivalent vaccine, the

Latest news

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story
...
Working together to achieve better patient pathways
Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.
How design can lead improvement within Pharma...